Canada markets closed

BioGend Therapeutics Co., Ltd. (6733.TWO)

Taipei Exchange - Taipei Exchange Delayed Price. Currency in TWD
Add to watchlist
37.45-0.15 (-0.40%)
At close: 01:30PM CST
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2023-12-31
2022-12-31
2021-12-31
2020-12-31
Total Revenue
134,646
109,908
31,446
9,269
1,393
Cost of Revenue
23,625
20,290
8,667
6,210
662
Gross Profit
111,021
89,618
22,779
3,059
731
Operating Expenses
Research Development
148,572
170,999
166,266
113,274
94,207
Selling General and Administrative
99,250
95,160
75,726
54,094
40,139
Total Operating Expenses
247,822
266,159
241,992
167,368
134,346
Operating Income or Loss
-136,801
-176,541
-219,213
-164,309
-133,615
Interest Expense
252
262
91
18
5
Income Before Tax
-129,322
-169,222
-213,895
-144,267
-145,594
Income Tax Expense
-8,304
-8,304
-8,396
0
-
Income from Continuing Operations
-121,018
-160,918
-205,499
-144,267
-145,594
Net Income
-116,059
-156,325
-184,455
-138,485
-145,594
Net Income available to common shareholders
-116,059
-156,325
-184,455
-138,485
-145,594
Basic EPS
-1.56
-1.30
-1.79
-1.37
-1.65
Diluted EPS
-1.56
-1.30
-1.79
-1.37
-1.65
Basic Average Shares
115,274
120,282
103,076
101,281
88,538
Diluted Average Shares
115,274
120,282
103,076
101,281
88,538